Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders.
Arvinas said it will present novel biomarker data from the Phase 1 clinical trial for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders.